Video

Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference Product

Author(s):

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.

Transcript

What can practices do to help manage the possibility of having to stock and manage multiple biosimilars for the same reference product?

Jensen: Unfortunately, I do not see this going away anytime soon until we have some more of that biosimilar parity legislation or more collaboration between health systems and payers on choosing preferred products. Until then, we're going to have to stock whatever biosimilars are covered by the patient's insurance in order to prevent that patient liability.

Related Videos
Christine Funke, MD
Drs Lillian L. Siu and Matthew G. Vander Heiden
Jaime Almandoz, MD, MBA
Martin Edelman, MD
Benjamin Chen, MD, PhD
Frederick L Locke, MD, Moffitt
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Benjamin Chen, MD, PhD
Kimberly Westrich, MA, chief strategy officer, NPC
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo